Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Afroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 623
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 339
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 182
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Xiaomin Zhang, Hui Zhang, Huixuan Lan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 91
Challenges and new technologies in adoptive cell therapy
Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 82
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Mohamad Hamieh, Jorge Mansilla‐Soto, Isabelle Rivière, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 829-843
Open Access | Times Cited: 69
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1871-1891.e6
Open Access | Times Cited: 47
Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development
Lin Tang, Sheng Pan, Xuyong Wei, et al.
Molecular Therapy (2023) Vol. 31, Iss. 11, pp. 3146-3162
Open Access | Times Cited: 47
Treatment strategies for clear cell renal cell carcinoma: Past, present and future
Junwei Yang, Kuansong Wang, Zhichun Yang
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 46
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis
Dai‐Shi Tian, Chuan Qin, Ming‐Hao Dong, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 4, pp. 966-987
Open Access | Times Cited: 23
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Patrizia Porazzi, Siena Nason, Ziqi Yang, et al.
Cancer Cell (2025)
Closed Access | Times Cited: 3
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 6
Open Access | Times Cited: 43
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Nathan Singh, Marcela V. Maus
Immunity (2023) Vol. 56, Iss. 10, pp. 2296-2310
Open Access | Times Cited: 23
Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
Pengfei Zhang, Dan Xie
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells
Ahmed Z. Gad, Jessica S. Morris, Lea Godret-Miertschin, et al.
Science Advances (2025) Vol. 11, Iss. 2
Open Access | Times Cited: 1
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
Bohan Zhang, Jiawen Wu, Hua Jiang, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 320-320
Open Access | Times Cited: 1
Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia
Catherine Pham‐Danis, A. Novak, Etienne Danis, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 482-502.e9
Open Access | Times Cited: 1
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Felix Korell, Trisha R. Berger, Marcela V. Maus
Med (2022) Vol. 3, Iss. 8, pp. 538-564
Open Access | Times Cited: 38
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model
Brandon D. Ng, Adhithi Rajagopalan, Anastasia I. Kousa, et al.
Blood (2024) Vol. 144, Iss. 2, pp. 171-186
Closed Access | Times Cited: 8
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
Anton Dobrin, Pieter L. Lindenbergh, Yuzhe Shi, et al.
Nature Cancer (2024) Vol. 5, Iss. 5, pp. 760-773
Open Access | Times Cited: 7
Immunotherapy for the treatment of multiple myeloma
Leora Boussi, Zachary M. Avigan, Jacalyn Rosenblatt
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control
Sophia Stock, Anna‐Kristina Klüver, Luisa Fertig, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 10, pp. 1706-1725
Open Access | Times Cited: 14
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma
Nathalie Roders, Cécilia Nakid-Cordero, Fabio Raineri, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 4, pp. 478-490
Open Access | Times Cited: 5
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
Brian J. Mog, Nikita Marcou, Sarah R. DiNapoli, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 755
Closed Access | Times Cited: 5
A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7
Mansour Poorebrahim, Isaac Quiros‐Fernandez, Frederik Marmé, et al.
Cancer Letters (2023) Vol. 566, pp. 216242-216242
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top